Akebia Therapeutics, Inc. - Common Stock (AKBA)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AKBA on Nasdaq
Shares outstanding
236,234,693
Price per share
$1.61
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
123,674,722
Total reported value
$337,699,735
% of total 13F portfolios
0%
Share change
+15,078,129
Value change
+$36,326,738
Number of holders
175
Price from insider filings
$1.61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akebia Therapeutics, Inc. - Common Stock (AKBA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.1% $34,523,231 15,141,768 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.4% $28,923,631 12,685,803 The Vanguard Group 31 Mar 2025
Satter Muneer A 2.6% $13,105,226 5,747,906 Satter Muneer A 31 Dec 2024
As of 30 Sep 2025, Akebia Therapeutics, Inc. - Common Stock (AKBA) has 175 institutional shareholders filing 13F forms. They hold 123,674,722 shares. of 236,234,693 outstanding shares (52%) .

Top 25 institutional shareholders own 44% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8% 18,797,058 +2.3% 0% $51,315,969
VANGUARD GROUP INC 6.6% 15,547,508 +6.4% 0% $42,444,697
STATE STREET CORP 5% 11,844,769 +48% 0% $32,336,219
GEODE CAPITAL MANAGEMENT, LLC 2.6% 6,184,951 +1.8% 0% $16,886,900
MORGAN STANLEY 1.8% 4,315,201 -19% 0% $11,780,499
RENAISSANCE TECHNOLOGIES LLC 1.7% 3,952,727 -5.8% 0.01% $10,790,945
UBS Group AG 1.5% 3,646,233 +470% 0% $9,954,217
Qube Research & Technologies Ltd 1.4% 3,206,184 +87% 0.01% $8,752,882
CITADEL ADVISORS LLC 1.3% 3,185,826 +37% 0.01% $8,697,305
MPM BIOIMPACT LLC 1.2% 2,889,125 0% 1.3% $7,887,311
MILLENNIUM MANAGEMENT LLC 1.2% 2,857,237 +32% 0.01% $7,800,257
FRANKLIN RESOURCES INC 1.1% 2,680,188 +0.48% 0% $7,316,914
NORTHERN TRUST CORP 1.1% 2,486,535 +16% 0% $6,788,241
Affinity Asset Advisors, LLC 1% 2,450,000 +26% 0.62% $6,688,500
Invesco Ltd. 1% 2,400,757 +528% 0% $6,554,067
Nuveen, LLC 0.97% 2,301,377 -15% 0% $6,282,760
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.92% 2,170,281 +190% 0% $5,924,867
ACADIAN ASSET MANAGEMENT LLC 0.91% 2,147,951 +59% 0.01% $5,862,000
Nantahala Capital Management, LLC 0.85% 2,000,000 0% 0.34% $5,460,000
CITIGROUP INC 0.81% 1,916,692 +1325% 0% $5,232,569
BANK OF AMERICA CORP /DE/ 0.76% 1,788,500 +61% 0% $4,882,605
GOLDMAN SACHS GROUP INC 0.75% 1,767,813 -55% 0% $4,826,130
DIMENSIONAL FUND ADVISORS LP 0.75% 1,766,691 +100% 0% $4,822,671
BARCLAYS PLC 0.5% 1,180,233 +20% 0% $3,222,037
Connor, Clark & Lunn Investment Management Ltd. 0.43% 1,020,668 -14% 0.01% $2,786,424

Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 1,043,310 $1,683,152 +$630,052 $1.61 7
2025 Q3 123,674,722 $337,699,735 +$36,326,738 $2.73 175
2025 Q2 108,291,108 $394,183,978 +$56,486,637 $3.64 157
2025 Q1 95,246,755 $182,865,666 +$63,362,812 $1.92 142
2024 Q4 67,845,406 $128,903,910 +$16,367,542 $1.90 120
2024 Q3 59,433,206 $78,446,645 +$886,944 $1.32 113
2024 Q2 56,272,261 $57,424,732 -$2,482,254 $1.02 100
2024 Q1 56,991,509 $104,293,412 +$2,027,480 $1.83 108
2023 Q4 54,644,403 $67,756,919 +$4,503,736 $1.24 83
2023 Q3 50,796,845 $57,906,145 +$685,292 $1.14 72
2023 Q2 50,244,290 $45,972,433 -$1,392,343 $0.92 76
2023 Q1 51,839,170 $29,049,633 -$98,488 $0.56 62
2022 Q4 52,253,997 $30,149,698 +$763,514 $0.58 70
2022 Q3 52,161,214 $16,491,885 -$1,812,681 $0.32 79
2022 Q2 57,164,176 $20,180,226 -$11,164,741 $0.35 82
2022 Q1 81,183,875 $58,271,372 -$32,826,439 $0.72 115
2021 Q4 96,816,883 $218,731,670 -$6,193,557 $2.26 128
2021 Q3 98,493,468 $283,669,170 -$32,502,791 $2.88 119
2021 Q2 106,173,637 $402,396,029 +$22,237,368 $3.79 131
2021 Q1 100,546,584 $340,303,134 -$8,611,368 $3.38 134
2020 Q4 103,249,738 $289,096,531 -$2,381,228 $2.80 134
2020 Q3 100,173,386 $251,381,270 -$415,118,712 $2.51 155
2020 Q2 111,597,128 $1,515,160,970 +$263,628,807 $13.58 184
2020 Q1 92,760,043 $703,124,581 +$65,005,544 $7.58 150
2019 Q4 84,238,825 $532,433,824 -$9,578,644 $6.32 147
2019 Q3 85,222,099 $334,110,423 -$7,128,495 $3.92 144
2019 Q2 86,927,834 $420,591,980 -$5,534,476 $4.84 145
2019 Q1 84,729,878 $693,928,655 +$34,225,709 $8.19 165
2018 Q4 81,089,428 $448,181,562 +$214,692,780 $5.53 154
2018 Q3 40,805,612 $360,286,694 -$30,324,254 $8.83 126
2018 Q2 42,400,943 $423,114,024 -$5,780,444 $9.98 136
2018 Q1 43,137,232 $411,768,819 +$80,498,894 $9.53 144
2017 Q4 33,696,160 $501,006,013 +$17,095,503 $14.87 128
2017 Q3 30,165,358 $593,266,094 +$67,324,611 $19.67 118
2017 Q2 27,265,524 $391,622,872 +$102,455,955 $14.37 115
2017 Q1 20,825,309 $191,436,543 +$23,185,087 $9.20 86
2016 Q4 20,209,985 $210,368,267 +$3,880,985 $10.41 91
2016 Q3 19,559,159 $176,944,259 +$636,790 $9.05 83
2016 Q2 19,605,356 $146,635,724 -$12,713,555 $7.48 89
2016 Q1 21,112,430 $190,508,000 +$34,261,987 $9.01 90
2015 Q4 15,836,572 $204,569,610 +$19,766,036 $12.92 88
2015 Q3 15,103,338 $145,886,918 +$23,189,587 $9.66 80
2015 Q2 12,209,438 $125,630,881 +$52,360,330 $10.29 70
2015 Q1 7,020,367 $77,139,761 -$2,020,205 $11.11 59
2014 Q4 7,115,554 $82,816,339 -$6,653,680 $11.64 55
2014 Q3 7,121,492 $157,598,296 -$855,471 $22.13 49
2014 Q2 7,180,472 $199,536,396 +$197,487,337 $27.79 50
2014 Q1 103,803 $2,030,000 +$2,030,000 $19.56 3